Published July 17, 2026 · Updated October 31, 2026

GLP-1 and peptide news

Regulatory actions, court cases and clinical-trial readouts on GLP-1 drugs and peptides, explained in plain English, with what each update does and doesn’t mean.

Every explainer cites the FDA document, court record, trial publication or company release it describes, and says when a result is company-reported rather than peer-reviewed. Card dates are when the news happened; each explainer shows its own published and updated dates. Updated October 31, 2026. Educational only, not medical advice.

November 2026

GLP-1 · Research review · November 3, 2026

Do GLP-1 drugs affect bone density? A placebo-trial meta-analysis finds a small spine signal, mostly from older agents

Pooling placebo-controlled trials, a Bone meta-analysis found a small, borderline drop in lumbar spine density and higher bone-breakdown markers, with no clear hip change; almost all trials tested older GLP-1 drugs, so the authors say the results do not extend to newer weight-loss medicines.

GLP-1 · Research review · November 2, 2026

How many people stop semaglutide because of side effects? About 6% vs 3% on placebo in a new trial meta-analysis

An updated meta-analysis of 10 placebo-controlled trials in adults without diabetes found more people stopped semaglutide than placebo because of adverse events (risk ratio 1.86); the serious adverse event estimate was imprecise, and certainty for the weight outcomes was rated low.

GLP-1 · Research review · November 1, 2026

Semaglutide and hair loss: a meta-analysis of trials finds more reports, with low-certainty evidence

A systematic review of randomized trials in Cureus found hair loss reported more often with semaglutide than with comparison groups (odds ratio 2.92, low certainty) and no clear difference in injection-site reactions. It does not show that semaglutide causes hair loss.

October 2026

GLP-1 · Research review · October 31, 2026

Does a GLP-1 drug change what people buy? Healthier grocery baskets early, back to baseline by 10 months

A small Swiss loyalty-card study in Diabetes, Obesity and Metabolism found more fruit, vegetables, fibre and protein in household purchases about 5 months after people started a GLP-1 drug, but by 10 months purchases no longer differed meaningfully from before treatment.

GLP-1 · Research review · October 31, 2026

CagriSema in type 2 diabetes: more weight loss than semaglutide, not much more blood-sugar control

A new meta-analysis of six trials in Diabetes, Obesity and Metabolism finds CagriSema adds about 6 points of weight loss over semaglutide 2.4 mg in type 2 diabetes, but the extra HbA1c drop is small and uncertain, and side-effect differences versus semaglutide remain unclear.

Side effects · Study · October 29, 2026

Ozempic vs Zepbound in FDA side-effect reports: what a new analysis can and can’t show

An analysis of 215,337 FDA adverse-event reports found stomach, kidney, pancreas and optic-nerve problems mentioned relatively more often with semaglutide, and hair loss with tirzepatide. Reports cannot show which drug is riskier; trials remain the better guide.

Peptides · Research review · October 31, 2026

Orthopaedic journal review: no controlled human evidence for TB-500 or BPC-157

A review in the Journal of the American Academy of Orthopaedic Surgeons finds no controlled human orthopaedic evidence for TB-500, thymosin beta-4 or BPC-157, warns TB-500 is often confused with thymosin beta-4, and tells surgeons to ask patients about peptide use. WADA’s 2026 list bans thymosin beta-4, TB-500 and BPC-157 in tested sport.

Weight loss · Study explainer · October 31, 2026

Foundayo in Japan: the top dose did no better than the middle one

In ATTAIN-J, a Lilly-funded trial of 238 Japanese adults published in The Lancet Diabetes & Endocrinology, orforglipron cut body weight 5.9% to 8.7% over 72 weeks versus 0.6% on placebo. The 36 mg dose lost no more than 12 mg but doubled nausea; the groups were small.

Weight loss · Study explainer · October 31, 2026

Two-thirds stopped Wegovy within a year in Israel

In a Diabetes, Obesity and Metabolism study of 34,309 Clalit Health Services members without diabetes who started Wegovy in early 2025, 36.5% had stopped by six months and 67.6% by a year. It is a records study: it shows who stopped, not why.

Switching · Paper explainer · October 31, 2026

Switching Wegovy to Zepbound: do you restart at 2.5 mg?

The labels say nothing about switching, and Zepbound starts everyone at 2.5 mg. An October 29 expert-consensus paper proposes starting some switchers higher. It calls that unvalidated expert opinion, resting on one 12-week, single-arm, Lilly-sponsored diabetes study and a model.

Heart · Study explainer · October 31, 2026

Does stopping a GLP-1 raise heart risk? What a VA study shows

In a BMJ Medicine study of 333,687 veterans with type 2 diabetes (published March 2026), people who stopped a GLP-1 lost most of the lower rate of heart attack, stroke and death seen in those who stayed on it. It is observational, so it can’t prove stopping caused it, and it didn’t study weight-loss-only users.

GLP-1 · Regulator · October 30, 2026

Japan warns on GLP-1 slimming use after ketosis cases

Japan’s PMDA reports ambulance cases of ketosis and ketoacidosis in people using GLP-1 drugs to slim down while eating very little, and tells clinicians to have patients stop and seek care if they vomit or cannot eat or drink.

Peptides · Study · October 29, 2026

Who is using BPC-157? A clinical-notes study

A preprint covered by AJMC finds documented BPC-157 use in US medical records rose 33-fold from 2020 to 2026, mostly for pain, often alongside other drugs. It counts use and cannot show the peptide works or is safe.

Alcohol · Study · October 30, 2026

Do GLP-1 users drink less? A national survey

In a JAMA Psychiatry survey covered by JAMA, 44% of GLP-1 users who drank said they drank less in the first three months. It is self-reported with no comparison group, so it can’t show the drug caused it.

Compounding · Study · October 30, 2026

What’s in compounded tirzepatide? Nebraska’s B12 data

A JAMA research letter on Nebraska prescription records found two-thirds of compounded tirzepatide prescriptions included a B12 form, and 99.5% were paid out of pocket. The records show prescriptions, not what was in the vial.

Older adults · Study · October 30, 2026

Is Wegovy safe if you’re frail? A SELECT trial analysis

A post hoc SELECT analysis covered by JAMA reports semaglutide’s heart benefit appeared consistent across frailty levels in 17,604 adults. But frailty was a records-based score, the average age was about 62, and muscle and bone weren’t measured.

Heart failure · Study · October 29, 2026

Tirzepatide vs semaglutide in heart failure (HFpEF): a new records study

A US claims study in 37,183 adults with HFpEF and type 2 diabetes linked tirzepatide to about 20% fewer heart failure hospital stays than semaglutide, with no difference in deaths. Observational, 5.1 months; no head-to-head trial exists.

Peptides · Telehealth · October 29, 2026

Hims & Hers previews Peptides+: what’s FDA-approved

Hims & Hers opened a waitlist for sermorelin, glutathione, B12, NAD+ and L-carnitine, with BPC-157 and TB-500 “to follow when allowable.” We checked where each stands with FDA and what the evidence shows.

Fatty liver (MASH) · Wegovy · Rezdiffra · October 29, 2026

Wegovy vs Rezdiffra for fatty liver, ahead of AASLD

Novo says it will present a real-world semaglutide vs resmetirom comparison at The Liver Meeting on November 6. What the two drugs’ biopsy trials showed, and why no head-to-head trial exists yet.

Safety · Australian coroner · October 29, 2026

Coroner links CJC-1295/ipamorelin to a fatal allergic reaction

A coroner in Victoria found an injection of the premixed peptides triggered actor Richard Norton’s fatal anaphylaxis in 2025, and asked Australia’s TGA to consider tighter limits. One case; asthma and a heart condition contributed.

Company results · Lilly earnings · October 29, 2026

Lilly’s Q3 2026: Mounjaro’s heart label, Zepbound and Foundayo sales

Lilly reported $10.7 billion of Mounjaro, $5.3 billion of US Zepbound and $184 million of Foundayo revenue for the quarter, and listed Mounjaro’s August approval to cut heart risk in type 2 diabetes. Sales are not efficacy data.

Insurance · Employer survey · October 28, 2026

Fewer employers cover GLP-1s for weight loss: what to check at open enrollment

WTW’s 2026 employer survey found GLP-1 coverage for weight loss fell from 57% to 53%, with 30% of covering employers considering dropping it. What to check in your 2027 plan, and the makers’ self-pay prices if coverage ends.

Regulatory · HHS notice · October 28, 2026

HHS makes FDA’s peptide compounding policy public

A draft enforcement discretion policy for pharmacies compounding six peptides, BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, under conditions. It was published in the Federal Register on October 30; the notice says comments can be submitted on regulations.gov until 2 weeks after publication (November 13, 2026, per regulations.gov). It does not make any of them an approved drug.

Clinical trial · Lilly topline · October 28, 2026

Retatrutide vs Ozempic: the first head-to-head trial (TRANSCEND-T2D-2)

Lilly reported about 20% weight loss vs 9.4% on Ozempic 2 mg and A1C down 2.2 vs 1.8 points at 80 weeks, on its efficacy estimand. It is a press release, not a published paper, and retatrutide is not approved.

Regulatory · Tracker · Updated October 28, 2026

FDA peptide status tracker: where 21 peptides stand

No peptide is on FDA’s 503A bulk-substance list. Which peptides sit on FDA’s safety-risk list, which went before its advisory committee, and which the new HHS policy names, each linked to an FDA source.

Legal · Court records · October 27, 2026

Lilly’s retatrutide lawsuits: status of all 11 cases

Lilly has sued 11 sellers and clinics over retatrutide. Three cases have ended, eight are open, and no court has decided whether Lilly’s claims are right. The suits target sellers, not buyers.

Clinical trial · Vanda Phase 3 · October 27, 2026

Tradipitant (NEREUS) for GLP-1 nausea and vomiting

Vanda Pharmaceuticals reported that tradipitant cut vomiting from 58.5% to 43.0% in its Phase 3 trial. It is approved only for motion sickness, and the trial used a harsher-than-normal dose start.

Legal · Reuters report · October 26, 2026

Judge declines to halt Lilly’s Zepbound vs Wegovy ads

Reuters reported that a federal judge in New Jersey denied Novo Nordisk’s request for a preliminary injunction against Lilly’s comparison ads; the lawsuit continues. What SURMOUNT-5 and a 41,381-person meta-analysis show.

Research · Heart Rhythm · October 26, 2026

94-trial analysis ranks semaglutide best for AFib reports

A network meta-analysis of 94 randomized trials found 18% fewer atrial fibrillation reports on injected semaglutide than on placebo. AF was mostly logged as a side effect, and certainty is rated low.

Clinical trial · NEJM · October 21, 2026

Retatrutide sleep apnea trials published

Two Lilly trials in NEJM found retatrutide cut breathing events more than placebo, by less in people with type 2 diabetes. The effect without diabetes looks similar to Zepbound’s; there is no head-to-head trial.

Regulatory · White House meeting log · October 19 to 27, 2026

Who met the White House on FDA’s peptide policy

Outside groups that asked the White House budget office for meetings before its review ended on October 27, including AAPM, Hims & Hers and the Alliance for Pharmacy Compounding, and who sits on AAPM’s boards.

Approval · EMA CHMP · October 15, 2026

EU committee backs Foundayo (orforglipron)

The European Medicines Agency’s CHMP recommended approving Foundayo across the EU for weight management and type 2 diabetes. How its US-label weight loss compares with Wegovy and Zepbound, in separate trials.

Approval · Korea MFDS · October 7, 2026

Korea approves efpeglenatide (Eppe) for obesity

Hanmi’s weekly GLP-1 shot was approved as the first Korean-developed GLP-1 obesity drug. Its label reports 9.02% weight loss vs 0.89% on placebo at 40 weeks. It is not FDA approved.

Guideline · WHO · October 7, 2026

WHO’s first child obesity guideline, and GLP-1s for teens

WHO published its first global guideline on child and adolescent obesity, drawing a line at age 10. Which GLP-1 drugs are US-approved by age, what teen trials show, and what is still unknown.

Regulatory · FDA decision · October 2, 2026

FDA says retatrutide is a drug, not a biologic

FDA again declined Lilly’s request to treat retatrutide as a biologic. What the drug-or-biologic label means for future copies, compounding and Lilly’s patent.

Earlier in 2026

Regulatory · May 29, 2026